Boehringer Ingelheim - Focus on NSCLC treatment options
Live Q&A - 22 September 2020 - 17:00-17:30
Date
14 Sep 2020Session
Boehringer Ingelheim - Focus on NSCLC treatment optionsPresenters
Tanja CuferAuthors
T. CuferAuthor affiliations
- Department Of Medical Oncology, University Clinic Golnik, University of Ljubljana,, 4208 - Golnik/SI
Resources
Resources from the same session
Welcome and introduction
Presenter: Tanja Cufer
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Uncommon EGFR mutations
Presenter: Xiuning Le
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma
Presenter: Silvia Novello
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
The Future of NSCLC
Presenter: Melissa Johnson
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
Key insights and closing remarks
Presenter: Tanja Cufer
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.